News
February 15 2025
The Series B financing will accelerate development of the existing pipeline
Details
EPOK Therapeutics Inc. (“EPOK” or the “Company”), today announced closing the Series B Ninancing. The round was led by the existing and new investors based in Canada and Italy. This Ninancing will accelerate the advancement of the lead asset EPRA-0322, a novel erythropoietin (EPO) receptor activating antibody, through preclinical to Phase -1 clinical study.
“We are excited about the noticeable progress, EPOK has made, and we are grateful to our committed investors for their continued support”, said Alessandra Gavirati, Chairperson of the EPOK board. This Ninancing also allows us to evaluate our novel anti-alphaKlotho antibody.
In conjunction with this round of Ninancing, EPOK also appointed Dr. Sanjeev Munshi as the new CEO effective December 2024.
EPOK also strengthened its board with the addition of Dr. Jagath Reddy Junutula, CEO Arvik Therapeutics, and Dr. Surya Sankuratri, former CEO of EPOK.
About EPOK
EPOK Therapeutics was founded in February 2023 by Sachdev Sidhu, Ph.D., and Orson Moe, MD, to develop engineered next-generation antibodies with improved speciNicity, safety, and more convenient dosing, against clinically validated therapeutic targets.
EPOK beneNits from two decades of research and innovation in antibody engineering and metabolic diseases, targeting anemia and hypophosphatemia associated with several genetic and acquired-induced diseases.
About EPRA-0322
EPRA-0322 is a novel engineered human antibody that specifically activates human EPO receptor to engage erythropoiesis signaling, leading to durable and stable hemoglobin levels. EPRA-0322 has the potential to be a safe, convenient, cost effective and durable treatment option for treating anemia.
PR Contact:
Sanjeev Munshi
CEO, EPOK Therapeutics Inc.
February 19, 2024
EPOK Therapeutics appoints four renowned experts to Scientific Advisory Board
Details
Toronto (Canada) / Hayward (CA, USA) – EPOK Therapeutics Inc., a preclinical stage biologics company developing advanced antibody formats targeting anemia and phosphate disorders, announced today the appointment of four renowned experts to its Scientific Advisory Board (“SAB”).
February 5, 2024
EPOK Therapeutics Inc. is Recognized as the Top Therapeutic Company in Canada by Life Sciences Review Top Therapeutic Company
Details
The company’s presence spans the innovation hubs of the bay Area in California and Texas and several development partners in the US and Europe, reinforcing its commitment to maintaining a global drug discovery and development perspective.
April 10, 2023
EPOK Therapeutics raises $9.0M in Seed Round Financing.
Details
EPOK Therapeutics Inc. (“EPOK” or the “Company”), a preclinical stage biotech company developing diabodies and antibody conjugates, announced today the completion of a $9.0M Seed Round financing, led by Canadian and Italian angel investors.
The proceeds from the financing will support the preclinical development of two proprietary drug candidates.
In conjunction with the financing, the Company appointed a new Board of Directors, with Alessandra Gavirati as Chair, Surya Sankuratri as CEO, co-Founder Sachdev Sidhu as Chief ScientiRic OfRicer, and Luigi Colombo as Chief Operation Officer. Co-Founder Orson Moe will serve as Chief Medical Officer.